American Urological Association--94th annual meeting. 1-6 May 1999, Dallas, USA

Traditional urological concerns, such as bladder instability, bladder cancer, prostate cancer and incontinence, were focused upon. In addition, significant attention was paid to erectile dysfunction, with varied developments in the field. Capsaicin was presented as having a role to play in the reduction of bladder instability, while a new formulation of oxybutinin was shown to improve female urge incontinence. The combination of topical estrogen and an oral agonist, phenylpropanolamine, also gave significant improvement in menopausal urinary urgency and incontinence. Tetrahydropyranyladriamycin (THPA) will possibly be effective for adequate prophylaxis against the recurrence of early bladder cancer. COX-2 receptor modulation has a role in the treatment of bladder cancer, whilst the endothelin receptor antagonist ABT-627 (Abbott International Ltd) may prove effective in the treatment of prostate cancer. Melanotan II (PNU-83757; Pharmacia and Upjohn Inc) and IC-351 (Icos Corp) are new compounds for the treatment of erectile dysfunction (ED), and more light is shed on a role for apomorphine for the same indication.